Image Sourced ShutterStock
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Nuheara has released its trademark IQbuds BOOST product
  • IQbuds BOOST is an advanced hearing aid product which boasts many features that other ear buds and hearing aids don’t have
  • The product will be available immediately in Northern Ireland and Scotland

Nuheara has released its trademark IQbuds BOOST product. The hearing aid product has been placed on the NHS Scotland hearing contract under the Hearable and Wearable category.

NHS Scotland is the publicly funded healthcare system in Scotland and this contract also incorporates the Northern Island region.

IQbuds BOOST is an advanced hearing bud product which boasts many features that other earbuds and hearing aids don’t have. At its core, the product is an accessible, cost-efficient hearing device targeted at people who require hearing assistance.

Nuheara is pleased to be able to supply NHS with IQbuds BOOST.

“We are delighted that, with immediate effect, we can begin supplying NHS in Scotland and Northern Ireland with IQbuds BOOST,” CEO, Justin Miller said.

IQbuds BOOST are immediately available and will be supplied and supported under the contract by its UK distributer, Puretone.

The device is 80 per cent cheaper than other hearing devices and aids which can cost up to thousands of dollars. Unlike standard hearing aids, IQbuds BOOST can connect to Bluetooth, stream music, suppress external noise, has tap touch controls and more.

“We take great confidence that health agencies such as NHS Scotland, see a growing need to now separately categorise hearable products within their hearing programs,” Justin said.

In regards to further distribution, the English NHS do not have a Hearable category. The company is currently discussing this possibility and will provide updates on progress.

NUH by the numbers
More From The Market Herald
Hexima (ASX:HXL) - CEO & Managing Director, Michael Aldridge

" Hexima’s (ASX:HXL) shares plummet on inconclusive clinical results for pezadeftide

Hexima's (ASX:HXL) shares have taken a hit today after phase two preliminary results for its pezadeftide…

" dorsaVi (ASX:DVL) extends agreement with QBE Australia

dorsaVi (ASX:DVL) has extended a deal with insurance provider QBE Australia for a further three years.

" New contract sees X2M Connect (ASX:X2M) cover 80pc of households in Okcheon, South Korea

X2M Connect (ASX:X2M) secures a repeat order to deliver water monitoring and control services to households…
Superloop (ASX:SLC) - Managing Director and CEO, Paul Tyler

" Superloop (ASX:SLC) completes Acurus acquisition

Superloop (ASX:SLC) has completed the acquisition of technology services company Acurus.